Physician profile
George D Robison
NPI 1578520821
$7,582.31
in general payments reported to CMS, 2019-2025
37 companies · $322 in 2025
The $322 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,130 · 2020: $565 · 2021: $475 · 2022: $977 · 2023: $670 · 2024: $444 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $3,520.00 | 2019 | |
| Abbvie INC. | $958.95 | 2019-2025 | Orilissa, Lo Loestrin Fe, Botox |
| Pfizer INC. | $524.20 | 2019-2024 | |
| Medtronic, INC. | $381.11 | 2021-2025 | Interstim |
| Astellas Pharma US INC | $328.81 | 2019-2024 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $172.51 | 2019-2023 | Acessa Provu System |
| Minerva Surgical, INC | $153.16 | 2019 | |
| Novo Nordisk INC | $135.66 | 2022-2024 | Wegovy |
| Myovant Sciences INC. | $123.24 | 2021-2022 | |
| Allergan, INC. | $121.33 | 2019-2021 | |
| Aspira Women'S Health INC | $107.56 | 2022-2024 | Ova1 |
| Coloplast Corp | $99.75 | 2019-2025 | Altis |
| Lilly USA, LLC | $96.83 | 2023-2025 | Zepbound, Mounjaro |
| Urovant Sciences INC | $77.06 | 2022 | |
| Amag Pharmaceuticals, INC. | $71.68 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $64.77 | 2023-2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $58.29 | 2023-2024 | Quviviq |
| Boston Scientific Corporation | $58.21 | 2023-2024 | Advantage System |
| Axonics, INC. | $48.49 | 2022-2024 | Axonics |
| Ethicon US, LLC | $43.71 | 2022 | |
| Smith+Nephew, INC. | $42.61 | 2025 | Stravix |
| Medtronic USA, INC. | $37.23 | 2019 | |
| Avion Pharmaceuticals | $36.58 | 2020 | |
| Daiichi Sankyo INC. | $34.52 | 2019-2020 | |
| Astellas Pharma Global Development | $29.91 | 2024 | Veozah |
| Vertex Pharmaceuticals Incorporated | $29.87 | 2025 | |
| Karl Storz Endoscopy-America | $27.81 | 2019 | |
| Evofem Biosciences, INC. | $27.39 | 2020-2021 | |
| Intuitive Surgical, INC. | $26.19 | 2019 | |
| Mayne Pharma Commercial LLC | $25.22 | 2025 | |
| Exeltis, USA INC. | $24.16 | 2025 | Slynd |
| Provepharm INC. | $19.44 | 2025 | Bludigo |
| Pacira Pharmaceuticals Incorporated | $17.40 | 2023 | Exparel |
| Kowa Pharmaceuticals America, INC. | $16.96 | 2023 | Seglentis |
| Osiris Therapeutics INC. | $14.51 | 2019 | |
| Coopersurgical, INC. | $13.80 | 2019 | |
| Zyla Life Sciences, INC. | $13.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Robison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.